Overview

A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer

Status:
Not yet recruiting

Trial end date:
2028-12-20

Target enrollment:

Participant gender:

Summary

This randomized, active-controlled, multicenter, open-label, Phase II study is designed to evaluate the efficacy and safety of ensatinib compared with Platinum-Based Chemotherapy as adjuvant treatment in ALK fusion positive II-IIIA stage non-small cell lung cancer after surgical resection

Phase:

Phase 2

Details

Lead Sponsor:

Sichuan University

Collaborator:

Betta Pharmaceuticals Co., Ltd.